Avidity Biosciences is a biotech company developing oligonucleotide-based therapies called antibody oligonucleotide conjugates (AOC). The company utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases.